Strong Revenue Growth TrendThe company reports very high year-over-year revenue growth percentage, indicating early product traction. For a diagnostic platform, sustained multi-quarter growth from a small base can signal improving market adoption and customer uptake, supporting longer-term scaling if execution continues.

Focused Diagnostic PlatformA clear strategic focus on personalized medicine and point-of-care diagnostics aligns with durable healthcare trends. Platform products plus consumables create potential recurring revenue streams and partnership opportunities with hospitals and pharma, which supports long-term commercial scalability if clinical validation and sales execution progress.

Cash Vs. Accounting Loss SignalFree cash flow loss being smaller than net loss suggests a portion of recorded losses are non-cash (e.g., accounting charges). This dynamic can extend runway versus headline net loss, providing management more time to execute commercialization or secure funding, which is important for a capital-intensive biotech ramp.

Bears Say

Very Weak Financial PerformanceAbsolute revenue remains immaterial (TTM ~329k) while the company reports large losses at gross, operating and net levels. This mismatch between revenue scale and cost base reduces resilience to shocks and means several quarters of consistent execution and new sales are required before profitability or self-funded growth become realistic.

Negative Shareholders' EquityA negative shareholders' equity position signals accumulated losses and constrains financial flexibility. With equity deficits, leverage is effectively high versus a small asset base, increasing refinancing and dilution risk and reducing the company's ability to absorb setbacks or fund growth without external capital injections.

Sustained Cash BurnPersistent and sizable operating and free cash flow deficits highlight ongoing funding needs. Continuous cash burn elevates short-to-medium term solvency risk, forces reliance on external financing or dilutive capital raises, and limits the firm's ability to invest organically in commercial expansion or R&D without securing new liquidity.

QLIFE FAQ

What was Qlife Holding AB’s price range in the past 12 months?

Qlife Holding AB lowest stock price was kr1.21 and its highest was kr5.74 in the past 12 months.

What is Qlife Holding AB’s market cap?

Qlife Holding AB’s market cap is kr29.71M.

When is Qlife Holding AB’s upcoming earnings report date?

Qlife Holding AB’s upcoming earnings report date is Feb 11, 2026 which is in 6 days.

How were Qlife Holding AB’s earnings last quarter?

Qlife Holding AB released its earnings results on Nov 12, 2025. The company reported -kr0.73 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.73.

Is Qlife Holding AB overvalued?

According to Wall Street analysts Qlife Holding AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Qlife Holding AB pay dividends?

Qlife Holding AB does not currently pay dividends.

What is Qlife Holding AB’s EPS estimate?

Qlife Holding AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Qlife Holding AB have?

Qlife Holding AB has 15,679,521 shares outstanding.

What happened to Qlife Holding AB’s price movement after its last earnings report?

Qlife Holding AB reported an EPS of -kr0.73 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.535%.

Which hedge fund is a major shareholder of Qlife Holding AB?

Currently, no hedge funds are holding shares in SE:QLIFE

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Qlife Holding AB

Qlife Holding AB (QLIFE) is a biotechnology company based in Sweden, specializing in the development of advanced diagnostic tools aimed at improving patient care and health outcomes. The company focuses on innovative solutions in the healthcare sector, particularly in the areas of personalized medicine and point-of-care diagnostics. Qlife's core products include its proprietary diagnostic platforms, which utilize advanced technology to deliver rapid and accurate health assessments.